A Phase II Multicenter Uncontrolled Trial of BAY43-9006 in Patients With Relapsed or Refractory Advanced Non-small Cell Lung Carcinoma.

Trial Profile

A Phase II Multicenter Uncontrolled Trial of BAY43-9006 in Patients With Relapsed or Refractory Advanced Non-small Cell Lung Carcinoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Apr 2017

At a glance

  • Drugs Sorafenib (Primary)
  • Indications Adenocarcinoma; Large cell carcinoma; Non-small cell lung cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Sponsors Bayer
  • Most Recent Events

    • 28 Jul 2009 Actual patient number (54) added as reported by ClinicalTrials.gov.
    • 20 Nov 2008 Status changed from active, no longer recruiting to completed, reported by ClinicalTrials.gov. The actual end date was April 2008.
    • 13 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top